  | 
							
								
								
	
	
		  | 
		
			 
			 
		 | 
	 
	 |  
	 |  
	
		
		
		
			
			
				| Naphazoline Hydrochloride  |  
				
				
				
				
				
				  |  
				| Naphazoline Hydrochloride  |  
				
				
				
				
				
				
				  |  
				Naphazoline Hydrochloride 
  Synonyms: Naphconforte  Naphazoline HCl
  CAS: 550-99-2 
  EINECS: 208-989-2 
  Assay: 99% min
  Standard: BP/EP/USP 
  Packing: 25kg/drum.
  Character: White crystalline powder. Melting point 255-260 ¡É. Soluble in 100 ml of water 40 grams of the product. Soluble in ethanol, slightly soluble in chloroform, insoluble in benzene and ether. Odorless, bitter taste.
  Usage: use as vasoconstrictor. A contraction of nasal blood vessels, reducing the vascular exudate, reducing nasal swelling and congestion. Clinically used to treat cold allergic rhinitis, inflammation of nasal congestion, acute and chronic rhinitis.
   
  |  
				
				
				
				
				
				
				
				  |  
				Naphazoline Hydrochloride 
  Synonyms: Naphconforte  Naphazoline HCl
  CAS: 550-99-2 
  EINECS: 208-989-2 
  Assay: 99% min
  Standard: BP/EP/USP 
  Packing: 25kg/drum.
  Character: White crystalline powder. Melting point 255-260 ¡É. Soluble in 100 ml of water 40 grams of the product. Soluble in ethanol, slightly soluble in chloroform, insoluble in benzene and ether. Odorless, bitter taste.
  Usage: use as vasoconstrictor. A contraction of nasal blood vessels, reducing the vascular exudate, reducing nasal swelling and congestion. Clinically used to treat cold allergic rhinitis, inflammation of nasal congestion, acute and chronic rhinitis.
   
  |  
				
				
				
					
						
							| Industrial field | 
							pharmaceutical | 
						 
					 | 
				 
				
			 
			
		 | 
		
		
		
			
				
				
				  |  
				
					| 
						
							
					 | 
				 
				 |  
				
				
				
					| 
						
					 | 
				 
				
					
						
							  |  
							
								
									
									
									
										| There are no existing companies to distribute selected chemical product |  
									
									 
									
								 | 
							 
							  |  
						 	
					 | 
				 
			 
			
			
		 | 
	 
 
									
								 |